CONTEXT AND OBJECTIVE: Scientific and technological development is crucial for advancing the Brazilian health system and for promoting quality of life. The way in which the Brazilian Ministry of Health has supported clinical research to provide autonomy, self-sufficiency, competitiveness and innovation for the healthcare industrial production complex, in accordance with the National Policy on Science, Technology and Innovation in Healthcare, was analyzed. DESIGN AND SETTING: Descriptive investigation, based on secondary data, conducted at the Department of Science and Technology, Ministry of Health.
INTRODUCTION
Scientific and technological development, guided by standards of excellence, ethics and equity, is crucial for advancing the Brazil- ian Unified Health System (Sistema Único de Saúde, SUS) and for improving quality of life. Article 200, paragraph V of the Brazilian Constitution describes one of the missions of SUS as "to increase scientific and technological development in its area of operation". 1 Integration between government activities, universities and businesses in the modern systems of science, technology and innovation that exist in industrialized countries has virtually eliminated the gap between discovery and application. This has also created a "virtuous circle" of positive feedback between research and development and socioeconomic status. The National Agenda was organized into 24 sub-agendas, and one of these was dedicated to "clinical research". This subagenda was organized into two sections. 
METHODS
This empirical study was based on secondary data obtained from the Decit management database system (PesquisaSaúde). 
RESULTS
An amount of almost R$ 140 million was assigned to 368 projects over the course of the time period studied. Table 1 or more of these diseases, which usually have very low priority in national healthcare programs. 16 In Brazil, however, they deserve special attention from researchers and healthcare policymakers. 17 The RNPC supports the clinical trials necessary for producing new national pharmaceuticals, principally those relating to neglected diseases. It is very important for the RNPC to promote scientific knowledge, thus meeting the demands of public concerns. months later, the investigators launched the National Diagnostic Kit, thereby promoting access to inputs from molecular biology to achieve diagnostic tests for the influenza A pandemic virus.
Moreover, biotechnological platforms have been deployed in three key national reference laboratories for influenza and three public health laboratories; equipment maintenance and human resources technical training has also been ensured. 21 The results described here demonstrate the Ministry of Health's progressive advances as a sponsor and key stakeholder in implementation and promotion of clinical research directed towards
Brazil's national requirements, largely due to creation of the RNPC.
Future healthcare policies should promote democratization of the clinical research funding processes in order to decentralize research investments throughout the country. Currently, many clinical studies are taking place through the RNPC and their conclusions will help to improve the Brazilian public health system.
Recently, a study showed how different research fields are prioritized for NIH (National Institutes of Health) support. 22 The authors concluded that, in 2006, the levels of disease-specific funding correlated only modestly with the burden of disease in the United States, and the correlation had not improved in relation to 1996 levels. The conditions receiving the most funding were AIDS and diabetes while on the other hand, the least amount of funding, relative to the burden of disease, was destined for depression and injuries. With a huge population, a plethora of diseases and rampant poverty, India is considered to be an "irresistible" location for clinical trials. 29 Pharmaceutical industry giants are attracted to India because of its 700,000 specialty hospital beds, 221 medical colleges and skilled English-speaking medical personnel. However, the biggest advantage is the low cost: trials for a standard drug in the United States can cost about $150 million and a similar drug could be tested in India at a 60% lower cost. 29 The status of clinical research in China was recently reviewed. 30 The 
